Chemomab Therapeutics CMMB
NASDAQ CMMB
$2.16 +0.09 (+4.35%)
At close: Aug 21, 2026 · 4:00 PM EDT

Chemomab Therapeutics (CMMB) Net Equity Issued and Repurchased (2018 - 2023)

Chemomab Therapeutics' (CMMB) quarterly Net Equity Issued and Repurchased came in at $3000.0 in Q3 2023, down 99.99% on a QoQ basis from $45.4 million in Q1 2021.

Chemomab Therapeutics (CMMB) Net Equity Issued and Repurchased (2018 - 2023) Analysis & Trends

Chemomab Therapeutics (CMMB) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $3000.0 in Q3 2023.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $45.4 million (changed N/A YoY) and the FY2019 annual result came in at $30.5 million, up 33.19% from the prior year.
  • Net Equity Issued and Repurchased eased to $3000.0 in Q3 2023, from $45.4 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $45.4 million in Q1 2021 to a low of $3000.0 in Q3 2023.
  • A 3-year average of $25.3 million and a median of $30.5 million in 2019 frame the typical range for Net Equity Issued and Repurchased.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Chemomab Therapeutics 13.62 Mn 3.25 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 3,000.00
Sep 30, 2023 3,000.00
Mar 31, 2021 45.37 Mn
Mar 31, 2021 45.37 Mn
Mar 31, 2019 30.50 Mn
Mar 31, 2019 30.50 Mn
Dec 31, 2018 10.91 Mn
Dec 31, 2018 10.91 Mn